nach oben

Erschienen in:

2017 | OriginalPaper | Buchkapitel

21. Übelkeit und Erbrechen

verfasst von : Pflegefachfrau C. Hlawatsch, PD Dr. med. K. Oechsle

Erschienen in: Onkologische Krankenpflege

Verlag: Springer Berlin Heidelberg

Einloggen, um Zugang zu erhalten

Zusammenfassung

Pflegende übernehmen vor, während und nach onkologischen Therapien eine wichtige Rolle bei der Prophylaxe und der Symptomkontrolle von Übelkeit und Erbrechen. Fundierte Kenntnisse zur Behandlung und Entstehung, sowie zu Auswirkungen von Übelkeit und Erbrechen sorgen für zielgerichtete pflegerische Interventionen und können an Patienten und Angehörige weitergegeben werden.

Vorheriges Kapitel Ernährung

Nächstes Kapitel Diarrhö und Obstipation

Aapro M et al. (2012) The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER). Ann Oncol 23: 1986–92

Basch E et al. (2011) Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 29: 4189–98

Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0; Published: May 28, 2009 (v4.03: June 14, 2010); U.S.DEPARTMENT OF HEALTH AND HUMAN SERVICES, National Institutes of Health, National Cancer Institute

Einhorn LH et al. (2011) Antiemetic therapy for multiple-day chemotherapy and additional topics consisting of rescue antiemetics and high-dose chemotherapy with stem cell transplant: review and consensus statement. Support Care Cancer 19 Suppl 1: S1–S4

Feyer PC, Maranzano E, Molassiotis A et al. (2011) Radiotherapy-induced nausea and vomiting (RINV): MASCC/ESMO guideline for antiemetics in radiotherapy: update 2009. Support Care Cancer 19: Suppl 1:S5–14

Gralla RJ et al. (1999) Recommendations for the Use of Antiemetics: Evidence-Based, Clinical Practice Guidelines. J Clin Oncol 17: 2971–2994

Grunberg SM, Hesketh PJ (1993) Control of chemotherapy-induced emesis. N Engl J Med 329: 1790–6

Grunberg SM et al. (2004). Incidence of chemotherapy- induced nausea and emesis after modern antiemetics: Perception versus reality. Cancer, 100, 2261–2268

Grunberg S et al. (2011) Single-Dose Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Cisplatin Therapy: Randomized, Double-Blind Study Protocol-EASE. J Clin Oncol 29: 1495–1501

Majem M et al. (2011). Perception of healthcare providers versus patient reported incidence of chemotherapy-induced nausea and vomiting after the addition of NK-1 receptor antagonists. Supportive Care in Cancer, 19, 1983–1990

Marx WM et al. (2013) Ginger (Zingiber officinale) and chemotherapy-induced nausea and vomiting: a systematic literature review. Nutr Rev71:245-54

Navari RM (2011) Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol 9: 188–95

NCCN Clinical Practice Guidelines in Oncology, Antiemesis, Retrieved Version 2.2014

Roila F et al. (2016) 2016 MASCC and ESMO guideline update for the prevention of chemotherpay-an radiotherpy -induced nausea and vomiting and of nausea and vomiting tin advanced cancer patients. Ann Oncol 27: Supp 5 v119–v133

Ryan JL et al. (2012) Ginger (Zingiber officinale) reduces acute chemotherapy-induced nausea: a URCC CCOP study of 576 patients. Support Care Cancer; 20:1479–89

Saito M, Aogi K, Sekine I et al. (2009) Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol 10: 115–24

Grunberg SM et al. (2011) Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity-state of the art. Support Care Cancer 19 Suppl 1: S43–7

Herrstedt J et al. (2011) Acute emesis: moderately emetogenic chemotherapy. Support Care Cancer19: S15–S23

Kris MG et al. (2011) Consensus recommendations for the prevention of vomiting and nausea following high-emetic-risk chemotherapy. Support Care Cancer 19 Suppl 1: S25–S32

Molassiotis A, Aapro M et al. (2014) J Pain Symptom Manage, 47(5): 839–848

Oliver I et al. (2011) Guidelines for the control of nausea and vomiting with chemotherapy of low or minimal emetic Potenzial. Support Care Cancer 19 Suppl: S33–S36

Roila F et al. (2011) Delayed emesis: moderately emetogenic chemotherapy (single-day chemotherapy regimens only). Support Care Cancer 19 Suppl 1: S57–S62

European Medical Oncology Society: (www.esmo.org Antiemetic Guidelines)

Multinational Association for Supportive Care in Cancer: www.mascc.org (Antiemetic Guidelines 2013)

National Comprehensive Cancer Network (www.nccn.org Antiemesis Guidelines)

Oncology Nursing Society: www.ons.org (Evidence based practice-PEP (Putting Evidence into Practice) – nausea/vomiting)

Titel: Übelkeit und Erbrechen
verfasst von: Pflegefachfrau C. Hlawatsch
PD Dr. med. K. Oechsle
Verlag: Springer Berlin Heidelberg
Buch: Onkologische Krankenpflege
Print ISBN: 978-3-662-53954-5

Electronic ISBN: 978-3-662-53955-2

Copyright-Jahr: 2017
DOI: https://doi.org/10.1007/978-3-662-53955-2_21

Springerpflege

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten